{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:49:29Z","timestamp":1790020169202,"version":"4.0.1"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002706","name":"AFA F\u00f6rs\u00e4kring","doi-asserted-by":"publisher","award":["130054"],"award-info":[{"award-number":["130054"]}],"id":[{"id":"10.13039\/501100002706","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007231","name":"Cancerf\u00f6reningen i Stockholm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007231","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We examined the efficacy and toxicity of the PI3K\u03b4 inhibitor idelalisib in combination with rituximab salvage therapy in consecutively identified Swedish patients with chronic lymphocytic leukemia (CLL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Results<\/jats:title><jats:p>Thirty\u2010seven patients with relapsed\/refractory disease were included. The median number of prior lines of therapy was 3 (range 1\u201311); the median age was 69\u2009years (range 50\u201389); 22% had Cumulative Illness Rating Scale (CIRS) &gt;6 and 51% had del(17p)\/<jats:italic>TP53<\/jats:italic> mutation. The overall response rate was 65% (all but one was partial response [PR]). The median duration of therapy was 9.8\u2009months (range 0.9\u201344.8). The median progression\u2010free survival was 16.4\u2009months (95% CI: 10.4\u201326.3) and median overall survival had not been reached (75% remained alive at 24\u2009months of follow\u2010up). The most common reason for cessation of therapy was colitis (<jats:italic>n<\/jats:italic>\u2009=\u20098, of which seven patients experienced grade \u22653 colitis). The most common serious adverse event was grade \u22653 infection, which occurred in 24 patients (65%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our real\u2010world results suggest that idelalisib is an effective and relatively safe treatment for patients with advanced\u2010stage CLL when no other therapies exist. Alternative dosing regimens and new PI3K inhibitors should be explored, particularly in patients who are double\u2010refractory to inhibitors of BTK and Bcl\u20102.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14065","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T06:27:27Z","timestamp":1690525647000},"page":"715-721","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Idelalisib (<scp>PI3K\u03b4<\/scp> inhibitor) therapy for patients with relapsed\/refractory chronic lymphocytic leukemia: A Swedish nation\u2010wide real\u2010world report on consecutively identified patients"],"prefix":"10.1111","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2785-2177","authenticated-orcid":false,"given":"Agnes","family":"Mattsson","sequence":"first","affiliation":[{"name":"Department of Oncology\u2010Pathology Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Internal Medicine S\u00f6dersjukhuset  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Eketorp","family":"Sylvan","sequence":"additional","affiliation":[{"name":"Department of Oncology\u2010Pathology Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Axelsson","sequence":"additional","affiliation":[{"name":"Department of Hematology Helsingborg's Hospital  Helsingborg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Ellin","sequence":"additional","affiliation":[{"name":"Department of Medicine Kalmar County Hospital  Kalmar Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5667-5264","authenticated-orcid":false,"given":"Christian","family":"Kjellander","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Internal Medicine Capio St G\u00f6ran Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0898-4940","authenticated-orcid":false,"given":"Karin","family":"Larsson","sequence":"additional","affiliation":[{"name":"Department of Hematology Uppsala University Hospital  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Lauri","sequence":"additional","affiliation":[{"name":"Department of Hematology Sunderby Hospital  Sunderbyn Lule\u00e5 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Lewerin","sequence":"additional","affiliation":[{"name":"Section of Coagulation and Hematology Sahlgrenska University Hospital  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Scharenberg","sequence":"additional","affiliation":[{"name":"Department of Hematology Skaraborgs Hospital Sk\u00f6vde  Sk\u00f6vde Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Love","family":"T\u00e4tting","sequence":"additional","affiliation":[{"name":"Department of Hematology Link\u00f6ping University Hospital  Link\u00f6ping Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemming","family":"Johansson","sequence":"additional","affiliation":[{"name":"Department of Oncology\u2010Pathology Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00d6sterborg","sequence":"additional","affiliation":[{"name":"Department of Oncology\u2010Pathology Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Hematology Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6614-5737","authenticated-orcid":false,"given":"Lotta","family":"Hansson","sequence":"additional","affiliation":[{"name":"Department of Oncology\u2010Pathology Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Hematology Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrg1879"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271171"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0366-1"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_2_10_6_1","unstructured":"Regionala Cancercentrum i Samverkan.Nationellt v\u00e5rdprogram kronisk lymfatisk leukemi KLL.2022.https:\/\/kunskapsbanken.cancercentrum.se\/globalassets\/cancerdiagnoser\/blod\u2010lymfom\u2010myelom\/kll\/vardprogram\/nationellt\u2010vardprogram\u2010kronisk\u2010lymfatisk\u2010leukemi\u2010kll.pdf."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"issue":"2","key":"e_1_2_10_8_1","first-page":"S19","article-title":"Approach to a patient with \u201cdouble refractory\u201d chronic lymphocytic leukemia: \u201cdouble, double toil and trouble\u201d (Shakespeare)","volume":"97","author":"Aronson JH","year":"2022","journal-title":"Am J Hematol"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005083"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1246727"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17032"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.200204"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144576"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1995.tb06377.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01460"},{"key":"e_1_2_10_17_1","unstructured":"HoechstetteraM KnaufbW DambachercS et al.Final results of IDELA PASS: a prospective non\u2010interventional post\u2010authorization safety study of idelalisib in Germany. Poster 1083368. XIX International Workshop on Chronic Lymphocytic Leukemia 2021 (iwCLL) Krak\u00f3w Poland. September 17\u201320 2021."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx031"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16271"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-535047"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2861"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000039"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S309171"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18736"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-850461"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007376"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T08:47:31Z","timestamp":1704530851000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/ejh.14065"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14065","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"2023-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}